US20100260854A1 - Granulate for the formulation of orodispersible tablets - Google Patents

Granulate for the formulation of orodispersible tablets Download PDF

Info

Publication number
US20100260854A1
US20100260854A1 US12/753,571 US75357110A US2010260854A1 US 20100260854 A1 US20100260854 A1 US 20100260854A1 US 75357110 A US75357110 A US 75357110A US 2010260854 A1 US2010260854 A1 US 2010260854A1
Authority
US
United States
Prior art keywords
granulate
weight
mixture
approximately
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/753,571
Other languages
English (en)
Inventor
Massimiliano Rossi
Riccardo Catalano
Silvia Boschetti
Paolo Andreatta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
E-Pharma Trento SpA
E PHARMA TRENTO SpA
Original Assignee
E PHARMA TRENTO SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40909993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100260854(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by E PHARMA TRENTO SpA filed Critical E PHARMA TRENTO SpA
Assigned to E-PHARMA TRENTO S.P.A. reassignment E-PHARMA TRENTO S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANDREATTA, PAOLO, BOSCHETTI, SILVIA, CATALANO, RICCARDO, ROSSI, MASSIMILIANO
Publication of US20100260854A1 publication Critical patent/US20100260854A1/en
Priority to US14/828,692 priority Critical patent/US9861581B2/en
Priority to US15/830,044 priority patent/US10632073B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/16—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by suspending the powder material in a gas, e.g. in fluidised beds or as a falling curtain

Definitions

  • This invention relates to a granulate for the formulation of orodispersible tablets, in particular the formulation of orodispersible tablets comprising pharmaceutical or nutritional active ingredients.
  • this invention relates to a granulate comprising mannitol and sorbitol in a weight ratio between 70:30 and 97:3.
  • This invention also relates to the use of the said granulate in the preparation of orodispersible tablets, to orodispersible tablets obtained using the said granulate and to a production process for obtaining the said granulate.
  • the orodispersible tablets obtained using the granulate according to this invention have high porosity and may comprise a high content of the active ingredient in comparison with the orodispersible tablets known in the art.
  • Orodispersible (OD) tablets are tablets taken orally which rapidly disintegrate in the mouth through the effect of the solvent action of saliva and the mechanical action of the tongue.
  • OD tablet formulations have better acceptability than traditional swallowable tablets, both in patients having difficulty with swallowing such conventional tablets (for example young children and the elderly), and patients with gastro-intestinal syndromes, who have greater problems in absorbing the active ingredients from solid pharmaceutical forms taken orally, which may be disturbed by the presence of the still undissolved solid tablet within the gastro-intestinal tract.
  • the disintegration of an OD tablet does not take place through a single mechanism, but involves various phenomena such as swelling of the disintegrant in contact with saliva, the formation of small channels promoted by the presence of pores in the tablet, the presence of effervescent substances, the mechanical action of the tongue, and so on.
  • the penetration of water (saliva) within an OD tablet is the first and fundamental step to disintegration, and for this it is necessary to find a compromise between the physical characteristics of the tablet and the chemical properties of the excipients used in the formulation.
  • U.S. Pat. No. 6,149,938 relates to a process for obtaining a useful granulate for the production of a solid form for oral use which rapidly disintegrates in the buccal cavity.
  • This granulate is prepared by the fluidised bed granulation of an aqueous solution comprising a water-soluble or water-dispersible polymer and a polyalcohol, which may optionally be mixed with other solid components, and subsequent drying in a fluidised bed dryer.
  • the polyalcohol preferably used is sorbitol, but others such as mannitol, xylitol, maltitol and so on may also be used; the quantity of polyalcohol varies between 50% and 90% by weight with respect to the total weight of the tablet obtained by compression of the granulate.
  • the tablets described in the examples include lubricants, have a weight of between 1 and 2 grams, and a disintegration time of between 30 and 140 seconds.
  • OD tablets disperse in the mouth within 3 minutes before swallowing
  • the US FDA has defined OD tablets as a solid form containing an active ingredient which disintegrates rapidly, normally in a matter of seconds, when placed on the tongue.
  • the disintegration of an OD tablet occurs between a few seconds and approximately one minute (Bandari et al., “Orodispersible tablet: An overview”, Asian Journal of Pharmaceuticals, January 2008).
  • Conventional OD tablets (as for example described in WO 03/009830 and in WO 00/27357) always include at least one disintegrant which swells as a result of water absorption and/or water channelling.
  • a disintegrant which is necessary for the disintegration of conventional OD tablets, has two disadvantages—on the one hand it increases the mass of the tablet restricting the possibility of adding the active ingredient in larger doses, and on the other it absorbs saliva, leaving a dry feeling in the oral cavity.
  • EP 1 800 669 relates to a solid pharmaceutical composition
  • a solid pharmaceutical composition comprising a central core containing the active ingredient and excipients for an orodispersible formulation and an orodispersible coating, for the oral, oral mucosal or sublingual administration of agomelatin.
  • the orodispersible coating is obtained with a specific diluent for orodispersible preparations, or using a conventional diluent with one or more added disintegrants.
  • the orodispersible diluent may comprise granules obtained by the co-atomization of lactose and starch (Strarlac®), or a atomized polyalcohol, for example sorbitol or mannitol, or a atomized mixture based on polyalcohols, for example excipients commercially marketed such as Partek® and Pharmaburst®.
  • lactose and starch lactose and starch
  • a atomized polyalcohol for example sorbitol or mannitol
  • a atomized mixture based on polyalcohols for example excipients commercially marketed such as Partek® and Pharmaburst®.
  • OD tablets prepared using this method and described in the examples the polyalcohol used is mannitol for direct compression or Starlac®.
  • the tablets obtained using this method have a maximum weight of 350 mg and in vitro tests describe a disintegration time of less than 3 minutes.
  • OD tablets for example in WO2007/104771 and U.S. Pat. No. 5,866,163
  • methods used for the production of conventional tablets include both methods used for the production of conventional tablets and alternative methods, such as fusion or lyophilisation processes in moulds, which are already known to those skilled in the art.
  • the production of OD tablets requires suitably designed manufacturing units because of the poor mechanical properties of the tablets.
  • Lubricants have to be added to increase the compressibility and flowability of the powders, but there is the disadvantage that these excipients reduce the wettability of the tablet and therefore the rate of disintegration.
  • the object of this invention is to provide a granulate for the formulation of orodispersible tablets which overcomes the problems described.
  • a granulate comprising mannitol and sorbitol in a specific weight ratio makes it possible to manufacture OD tablets which disintegrate rapidly, in times less than 30 seconds, in contact with saliva in the oral cavity, with good palatability.
  • the Applicant has found that the granulate according to this invention obtained from the combination of mannitol and sorbitol, two readily available and inexpensive polyalcohols, has made it possible to obtain an OD tablet which at the same time disintegrates and/or dissolves in the oral cavity without the need to add a disintegrant.
  • Mannitol and sorbitol are highly hygroscopic and soluble in water, which is essential for oral administration where the quantity of liquid (saliva) available for disintegration is fractions of a millilitre.
  • OD tablets obtained with the granulate according to this invention may have a very much greater mass, up to 2000 mg and even more, in comparison with conventional OD tablets comprising a disintegrant, whilst keeping disintegration times below 30 seconds.
  • the Applicant has therefore observed that the possibility of obtaining tablets having a mass of more than 2 g also includes the possibility of adding a greater quantity of the active ingredient to the formulation in comparison with conventional tablets.
  • the increase in tablet size makes it possible to apply less pressure per unit surface area during the compression step, and as a consequence to obtain greater porosity.
  • the Applicant has found that the granulate according to this invention has good mechanical properties, with high compressibility and flowability, which means that it can be used without the addition of lubricating agents.
  • this invention relates to a granulate of a mixture of mannitol and sorbitol in a ratio by weight of between approximately 70:30 and approximately 97:3.
  • the Applicant has found that use of the granulate according to this invention makes it possible to obtain tablets with a high compressibility index.
  • the compressibility index is given by the ratio between the hardness of the tablet and the compression force.
  • the tablets obtained using the granulate according to this invention have greater hardness and lower density. Greater hardness imparts the necessary strength upon the tablet to withstand mechanical stresses during the processes of production and packaging without breaking up. Lower density imparts greater porosity on the tablet and therefore a greater rate of disintegration because water penetrates within the OD tablet more quickly.
  • this invention relates to an OD tablet comprising a granulate of a mixture of mannitol and sorbitol in a ratio by weight of between approximately 70:30 and approximately 97:3.
  • the Applicant has also observed that the characteristics of the granulate according to this invention are advantageously obtained through a fluidised bed granulation process by controlling the dimensions of the mannitol and sorbitol particles, the quantity of water, and the temperature and humidity of the air used in the granulation process.
  • this invention relates to a process for producing a granulate comprising mannitol and sorbitol, the said process comprising the following steps:
  • FIG. 1 shows the in vitro and in vivo disintegration times of tablets 10 according to the invention as a function of hardness, and comparison tablets 11 described in Example 5 below.
  • this invention may show one or more of the preferred characteristics described below.
  • the granulate according to this invention comprises mannitol and sorbitol in a ratio by weight of between 80:20 and approximately 95:5, and even more preferably approximately 90:10.
  • the granulate according to this invention has an average particle size of between 50 ⁇ m and 500 ⁇ m, preferably between 150 ⁇ m and 350 ⁇ m.
  • the granulate tends to become compacted because of prevalence of weak forces (of the Van der Waals, dipole-dipole and hydrogen bond type) over the weight force of the particle and low flowability problems occur.
  • the granulate shows an increase in the inter-particle empty spaces, which increases the apparent volume. Apparent volume is defined as the space occupied by a particular quantity of granulate when poured and caused to fall into a container of cubic or rhomboidal shape.
  • the granulate according to this invention has a density of less than 1 g/cm 3 , and more preferably less than 0.75 g/cm 3 .
  • the low density of the granulate is an indication of its high porosity, and makes it possible to obtain OD tablets with reduced disintegration times, increased hardness (imparting the ability to withstand mechanical stresses) and good compressibility.
  • the granulate according to this invention has a very low residual moisture content, less than 0.20% by weight relative to the weight of the granulate. More preferably the granulate according to this invention has a residual moisture content equal to or lower than 0.10% by weight relative to the weight of the granulate.
  • the Applicant has observed that for residual moisture values slightly above that specified (up to 0.50%) there are increases in the hardness of the tablets over time which have an adverse effect on the rate of disintegration in the mouth, while at residual moisture values well beyond those specified (up to 1.00% and more) the stability of the final tablet is compromised.
  • the granulate according to this invention is prepared using a fluidised bed granulation technique. Under specific conditions this type of granulation makes it possible to obtain the product with the desired characteristics.
  • the process of producing the granulate according to this invention comprises the following steps:
  • the Applicant has observed that the use of a mixture of mannitol and sorbitol having an average mixture particle size of less than 200 ⁇ m, preferably between 100 ⁇ m and 150 ⁇ m, makes it possible to obtain a final granulate having a greater compressibility index. Because mannitol is always the main component in the mixture (in a quantity of between 70% and 97% by weight) with respect to sorbitol, which is always the secondary component (in a quantity between 30% and 3% by weight), the latter may also be used in the form of a powder having an average particle size of more than 200 ⁇ m. In particular the Applicant has found that better results are obtained with a mixture comprising mannitol having an average size of less than 100 ⁇ m and sorbitol having an average size between 200 ⁇ m and 250 ⁇ m.
  • the preferred quantity of water is between 10% and 30% by weight, more preferably between 15% and 25% by weight with respect to the weight of the mixture of mannitol and sorbitol in the said mixture.
  • the temperature of the air introduced into the fluidised bed granulator is higher than 60° C., more preferably between 65° C. and 75° C., and even more preferably around 70° C.
  • the relative moisture content of the air introduced into the fluidised bed granulator is less than 5000 ppm, preferably equal to or lower than 1000 ppm.
  • temperatures equal to or higher than 80° C. may cause chemical and physical changes in the granulate, with the occurrence of fusion and yellowing.
  • temperatures below 60° C. would require long drying times, which, although in principle practicable, are not convenient from the industrial point of view.
  • optimum drying times from the industrial point of view are less than 30 minutes, preferably equal to or lower than 20 minutes.
  • the choice of relative humidity values for the air introduced into the fluidised bed granulator also depends on drying temperature and times, and the desired residual moisture content.
  • the granulate obtained through the process according to this invention has perfect flowability and has a regular particle size which permits precise dosing.
  • the granulate obtained through the process according to this invention also has high compressibility.
  • Compressibility is measured as the ratio between the hardness of the tablet and the compression force applied in order to obtain that hardness. This ratio is defined as the “Compressibility Index” (CI).
  • the Applicant has found that the granulate according to this invention has a compressibility index of more than 4.5, a value which is not found with other known excipients for the production of orodispersible tablets.
  • a high CI value means that greater hardness can be obtained with less compression force. This avoids the addition of a lubricant among the excipients, which, as known to those skilled in the art, is used to prevent the granulate to stick to the punches and walls of the mould during the compression step and ensures that the particles comprising the granulate can flow.
  • This invention also relates to an OD tablet comprising the granulate according to this invention.
  • the tablet according to this invention comprises at least 50% by weight of granulate, preferably between 50% and 99% by weight.
  • the presence of a quantity of granulate of more than 50% by weight ensures a good compression yield regardless of the mechanical characteristics of the active ingredient used, and makes it possible to achieve good compression yields even with difficultly compressible active ingredients. Below this percentage the compression yield may decrease appreciably because of the lack of contact between the particles of the granulate according to this invention.
  • the Applicant has in fact observed that using the granulate according to this invention the mass of the tablets is greater, and the rate of disintegration is also greater. This happens because disintegration of the tablet according to the invention depends only on contact between the granulate and water (saliva). Because the latter can penetrate the tablets with greater porosity more quickly, the volume and as a consequence the mass of the tablets can be increased without a corresponding increase in disintegration times.
  • the tablets according to this invention may comprise any active ingredient which is suitable for oral administration.
  • active ingredients which may be advantageously used in preparing tablets according to this invention are non-steroidal anti-inflammatory drugs (NSAIDs), anxiolytics, antiemetics, antihistaminics, proton pump inhibitors, and so on.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • anxiolytics anxiolytics
  • antiemetics antiemetics
  • antihistaminics antihistaminics
  • proton pump inhibitors proton pump inhibitors
  • the active ingredients formulated in OD tablets may advantageously be coated with one or more layers of a polymer, either to mask the unpleasant taste of the active ingredient or to obtain gastric protection or prolonged/delayed release over time.
  • a polymer which are advantageously used to coat the active ingredients used in preparation of the tablets according to this invention are for example Eudragit (Evonik), Methocel (Dow), Kollicoat (BASF), Klucel (Signet), Aqualon, Aquacoat, Lustreclear (FMC), Opadry (Colorcon), Spectracel, Spectrablend (Sen-sient).
  • the tablet according to this invention may also comprise other ingredients typically used in the preparation of orodispersible tablets such as for example diluents, sweeteners, flavourings and the like.
  • Suitable diluents comprise lactose, starch, dextrose, xylitol, and so on.
  • suitable sweeteners comprise aspartame, saccharin, acesulphame, and so on.
  • flavourings comprise grapefruit flavour, raspberry flavour, lemon flavour, orange flavour, caramel flavour, vanilla flavour, cream flavour, and the like.
  • a mixture of powdered mannitol (average size less than 100 ⁇ m) and powdered sorbitol (average size between 200 ⁇ m and 250 ⁇ m) in a weight ratio of 9:1 was used to prepare the granulate using different granulation methods.
  • the mixture was first compacted by a tablet press into slugs having a diameter of approximately 20-30 mm. Using different compression forces, slugs T A , T B , T C having respective hardness of 20N, 50N and 120N were obtained. The slugs were then broken up using an oscillating granulator and sieved through a 1000 ⁇ m sieve. Granulates A, B and C obtained from slugs T A , T B , T C respectively had the average sizes and densities indicated in Table 1.
  • Granulate D had an average size and density as indicated in Table 1 below.
  • Granulate E had an average size and density as indicated in Table 1 below.
  • the five granulates A-E so obtained were used to prepare respectively five tablets 1-5 in a dose of 2.6 g in a tablet press equipped with punches having a diameter of 25 mm exerting a compression force of 65 KN.
  • the hardness and thickness values for the tablets so obtained are shown in Table 2 below.
  • Granulate E according to this invention was compared with a series of commercial excipients ready for compression. The comparison was made by comparing a series of tablets as described in Example 1 and measuring the resulting hardness of each tablet obtained. The results are summarised in Table 3 below.
  • Granulate E according to this invention was prepared following the procedure described in Example 1, varying the process conditions (temperature and humidity) of the air. The results are summarised in Table 4 below.
  • Test granulates F-H were prepared using the procedure described in Example 1, but varying drying times so as to obtain a different residual moisture content, as shown in Table 5.
  • the three granulates F-H so obtained were used to prepare three lots of tablets 6-8 respectively with a dosage of 2.6 g in a tabletting machine having punches of diameter of 25 mm exerting a compression force of 65 KN.
  • the hardness values of the tablets so obtained were measured immediately after preparation (T0), after one month (T1), and after three months (T3). Table 6 below summarises the values obtained.
  • the data in Table 6 clearly showed that the residual moisture content of the granulate has an appreciable effect on the hardness of the tablets over time.
  • the tablets in comparison lots 7 and 8 proved unusable one month and/or three months after preparation.
  • the increased hardness of the tablets in lot 7 had an adverse effect on the disintegration rate in the mouth while the tablets in lot 8 were already degraded after one month.
  • the tablets in lot 6 obtained from granulate according to this invention showed constant values for hardness over time and no degradation.
  • Granulate E according to this invention was used to prepare tablets of different hardness in the presence or absence of disintegrants as shown in Table 7.
  • in vitro tablets 10 according to the invention showed an increase in disintegration time with increased hardness (from 40 to 100 seconds) and in all cases always longer than the disintegration time of comparison tablets 11 (30 and 55 respectively). Wholly negative results were also expected from the in vivo test following these results.
  • comparison tablets 11 behaved consistently with the in vitro results, with similar disintegration times (20 and 50 respectively), while tablets 10 according to the invention showed completely different and positive disintegration times, much shorter than those for tablets 11 (15 and 25 respectively).
  • the graph in FIG. 1 shows the different trends shown by tablets 10 according to the invention and comparison tablets 11, in vitro and in vivo respectively, with increasing hardness.
  • Granulate E was used to prepare two series of tablets in the presence or absence of disintegrants as shown in Table 9.
  • the tablets used in the test were produced in order to simulate a tablet containing an active ingredient (not actually present) which would require a coating (for example in order to mask its unpleasant flavour).
  • Syloid FP, sodium lauryl sulphate, stearic acid and Eudragit Epo were used to prepare the polymer coating.
  • Tablets 12 and 13 were used in a test panel of 25 volunteers to check the in vivo disintegration rate and to have an objective evaluation of the palatability of the product.
  • the organolectic characteristics about which the participants in the test had to give their opinion were the following:
  • the disintegration time for tablets 13 according to the invention proved to be significantly less than the disintegration time for comparison tablets 12 containing disintegrants. In addition to this, tablet 13 according to the invention proved to be more acceptable overall, with a disintegration time of almost 50% less than that of comparison tablet 12.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
US12/753,571 2009-04-09 2010-04-02 Granulate for the formulation of orodispersible tablets Abandoned US20100260854A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/828,692 US9861581B2 (en) 2009-04-09 2015-08-18 Granulate for the formulation of orodispersible tablets
US15/830,044 US10632073B2 (en) 2009-04-09 2017-12-04 Granulate for the formulation of orodispersible tablets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425135.2A EP2238974B9 (en) 2009-04-09 2009-04-09 Granulate for the formulation of orodispersible tablets
EP09425135.2 2009-04-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/828,692 Continuation US9861581B2 (en) 2009-04-09 2015-08-18 Granulate for the formulation of orodispersible tablets

Publications (1)

Publication Number Publication Date
US20100260854A1 true US20100260854A1 (en) 2010-10-14

Family

ID=40909993

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/753,571 Abandoned US20100260854A1 (en) 2009-04-09 2010-04-02 Granulate for the formulation of orodispersible tablets
US14/828,692 Active US9861581B2 (en) 2009-04-09 2015-08-18 Granulate for the formulation of orodispersible tablets
US15/830,044 Active 2030-04-06 US10632073B2 (en) 2009-04-09 2017-12-04 Granulate for the formulation of orodispersible tablets

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/828,692 Active US9861581B2 (en) 2009-04-09 2015-08-18 Granulate for the formulation of orodispersible tablets
US15/830,044 Active 2030-04-06 US10632073B2 (en) 2009-04-09 2017-12-04 Granulate for the formulation of orodispersible tablets

Country Status (10)

Country Link
US (3) US20100260854A1 (pt)
EP (1) EP2238974B9 (pt)
CA (1) CA2697576C (pt)
CY (1) CY1114183T1 (pt)
DK (1) DK2238974T3 (pt)
ES (1) ES2422281T3 (pt)
HR (1) HRP20130805T2 (pt)
PL (1) PL2238974T3 (pt)
PT (1) PT2238974E (pt)
SI (1) SI2238974T1 (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835488B2 (en) 2016-06-16 2020-11-17 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11077055B2 (en) 2015-04-29 2021-08-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2422281T3 (es) * 2009-04-09 2013-09-10 E Pharma Trento Spa Granulado para la formulación de comprimidos bucodispersables

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5866163A (en) * 1993-09-10 1999-02-02 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US6149938A (en) * 1997-07-25 2000-11-21 Elan Pharma International Limited Process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets and compositions obtained thereby
US6165511A (en) * 1996-04-22 2000-12-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Polyol composition
US20030002912A1 (en) * 2001-06-01 2003-01-02 David Morpeth Wax applicator
US20060025584A1 (en) * 2002-07-03 2006-02-02 Olli-Pekka Eroma Crystallization of polyol compositions, crystalline polyol composition product and use thereof
US20060251716A1 (en) * 2001-12-17 2006-11-09 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US20070212417A1 (en) * 2006-03-07 2007-09-13 Cherukuri S R Compressible resilient granules and formulations prepared therefrom

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
FR2787110B1 (fr) * 1998-12-11 2001-02-16 Roquette Freres Sorbitol pulverulent et son procede de preparation
ATE346590T1 (de) 2001-07-26 2006-12-15 Ethypharm Sa Umgehüllte allylamine oder benzylamine enthaltende granulate, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die umgehüllten granulate
PL1799195T3 (pl) * 2004-08-12 2016-09-30 Granulki zawierające paracetamol, nlpz i alkohol cukrowy wytwarzane przez wytłaczanie ze stopionego materiału
FR2894475B1 (fr) 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
FR2898492B1 (fr) 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
EP2170273B1 (de) * 2007-06-06 2014-11-26 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
ES2422281T3 (es) * 2009-04-09 2013-09-10 E Pharma Trento Spa Granulado para la formulación de comprimidos bucodispersables

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866163A (en) * 1993-09-10 1999-02-02 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US6165511A (en) * 1996-04-22 2000-12-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Polyol composition
US6149938A (en) * 1997-07-25 2000-11-21 Elan Pharma International Limited Process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets and compositions obtained thereby
US20030002912A1 (en) * 2001-06-01 2003-01-02 David Morpeth Wax applicator
US20060251716A1 (en) * 2001-12-17 2006-11-09 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US20060025584A1 (en) * 2002-07-03 2006-02-02 Olli-Pekka Eroma Crystallization of polyol compositions, crystalline polyol composition product and use thereof
US20070212417A1 (en) * 2006-03-07 2007-09-13 Cherukuri S R Compressible resilient granules and formulations prepared therefrom

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Ahmed and Shaikh, Pakistan Journal of Pharmaceutical Sciences Vol. 16: 13-16 (2003). *
Molokhia et al., Drug Development and Industrial Pharmacy, 13(9-11), 1933-1946 (1987). *
Product Bulletin, COMPRESSOL SM, SPI Pharma PB329-CompressolSM 3/2009 http://www.spipharma.com/uploads/Compressol%20SM%20USP-%20PIB329.pdf accessed on 6/27/2014 *
SPI Pharma, Mannogem(TM) Mannitol Technical Bulletin (2007). *
Technical Bulletin, COMPRESSOL SM, SPI Pharma T135-Compressol SM (1/2009) http://www.spipharma.com/uploads/Compressol-SM%20T135.pdf accessed on 6/27/2014 *
U.S. Pharmacopeia Chapter 1174, Powder Flow, accessed Jan. 18, 2012. *
Yu et al., Journal of Pharmaceutical Sciences, 87: 774-777 (1998). *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077055B2 (en) 2015-04-29 2021-08-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11986554B2 (en) 2015-04-29 2024-05-21 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10835488B2 (en) 2016-06-16 2020-11-17 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Also Published As

Publication number Publication date
EP2238974B1 (en) 2013-06-05
US9861581B2 (en) 2018-01-09
ES2422281T3 (es) 2013-09-10
US10632073B2 (en) 2020-04-28
EP2238974B9 (en) 2014-05-21
PL2238974T3 (pl) 2013-09-30
US20180092849A1 (en) 2018-04-05
PT2238974E (pt) 2013-07-09
CY1114183T1 (el) 2016-08-31
EP2238974A1 (en) 2010-10-13
CA2697576A1 (en) 2010-10-09
US20160045438A1 (en) 2016-02-18
HRP20130805T1 (en) 2013-09-30
DK2238974T3 (da) 2013-08-26
HRP20130805T2 (en) 2013-10-11
SI2238974T1 (sl) 2013-09-30
CA2697576C (en) 2017-07-11

Similar Documents

Publication Publication Date Title
US6740339B1 (en) Quickly disintegrating solid preparations
EP2572705B1 (en) Orodispersible tablets
US6287596B1 (en) Quickly disintegratable compression-molded materials and process for producing the same
EP1809251B1 (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
JP2001058944A (ja) 速崩壊性固形製剤
JP2006070046A (ja) 速崩壊性固形製剤
RU2500388C2 (ru) Маннит, распадающийся в полости рта
US10632073B2 (en) Granulate for the formulation of orodispersible tablets
US20100092564A1 (en) Composition of and Method for Preparing Orally Disintegrating Tablets
JP2002255796A (ja) 口腔内速崩壊型錠剤及びその製造方法
JP2003176242A (ja) 速崩壊性圧縮成型物及びその製造法
JP7012492B2 (ja) 錠剤およびその製造方法
JP5080856B2 (ja) 経口投与用錠剤
JP2005306770A (ja) 口腔内速崩壊型製剤及びその製造方法
TWI776177B (zh) 口腔內崩散錠的製造方法及口腔內崩散錠
Rai et al. A REVIEW ON: ORAL DISPERSIBLE TABLETS

Legal Events

Date Code Title Description
AS Assignment

Owner name: E-PHARMA TRENTO S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSSI, MASSIMILIANO;CATALANO, RICCARDO;BOSCHETTI, SILVIA;AND OTHERS;REEL/FRAME:024193/0283

Effective date: 20100324

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION